QuantHealth Bolsters Executive Leadership Team to Support Its Expanding Product Portfolio and Growing Client Footprint

Audio By Carbonatix

TEL AVIV, Israel--(BUSINESS WIRE)--Mar 24, 2026--

QuantHealth, a pioneer in AI-driven clinical trial simulation, today announced the expansion of its executive leadership team with the appointments of Nadav Weinberg as Senior Vice President of Sales and Heather Adamson as Head of Marketing and Communications. The announcement comes as the company enters its next phase of commercial growth following rapid customer adoption and the recent launch of its real-time clinical trial simulation solution.

As the SVP of Sales, Weinberg will help lead QuantHealth's global sales efforts and drive continued customer growth across the pharma and biotech sectors. He brings more than 15 years of experience scaling high-growth startups, most recently serving as Chief Commercial Officer at Velsera, a precision medicine software platform at which he led its global go-to-market strategy. Prior to Velsera, Weinberg held various leadership roles at Tempus AI, notably leading its growth in oncology registries and infectious disease.

Adamson brings an impressive track record of leading brand and business growth for established and emerging healthcare AI companies, including IBM and Integra Connect, as well as deep expertise in clinical-to-commercial life sciences marketing. At QuantHealth, she will leverage this dynamic experience to lead global growth marketing, which will focus on accelerating new and expansion deals and elevating its market leadership.

"Following a landmark year for the business in 2025, QuantHealth is entering an exciting phase of growth and innovation," says Orr Inbar, CEO and co-founder of QuantHealth. “The global clinical trials market is projected to reach $175 billion by 2035. As a result of this growth, demand for technologies that advance clinical trials is accelerating. As we look to meet this demand and expand our market presence, Heather’s and Nadav’s expertise in scaling organizations and driving commercial execution will be invaluable.”

The addition of Weinberg and Adamson strengthens QuantHealth's position to unlock greater predictive insight and help its partners bring life-changing therapies to market faster as the company continues to advance its AI-powered clinical simulation platform.

"Joining an innovative company like QuantHealth is an opportunity to be at the forefront of transforming the next generation of drug development," says Nadav Weinberg, SVP of Sales at QuantHealth. "I am looking forward to building upon its existing momentum and deepening our relationships with our partners, exploring new approaches that enable them to make smarter clinical and commercial decisions.”

The new executive appointments follow several recent company milestones, including 8X financial growth, surpassing 600 simulated clinical trials, and a strategic investment from Sanofi Ventures, the venture capital arm of global healthcare leader Sanofi. To learn more about QuantHealth and its suite of solutions for drug development, please visit quanthealth.ai.

About QuantHealth

QuantHealth is an AI-driven clinical trial simulation company that helps pharmaceutical companies design faster, more successful trials using real-world data and predictive modeling. With access to over 350 million patient records and proprietary AI algorithms, QuantHealth’s platform simulates trials at scale to optimize protocols, reduce risk, and accelerate timelines.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260324314748/en/

CONTACT: SolComms

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA ISRAEL MIDDLE EAST

INDUSTRY KEYWORD: TECHNOLOGY CLINICAL TRIALS HEALTH TECHNOLOGY PROFESSIONAL SERVICES BIOTECHNOLOGY HEALTH DATA ANALYTICS PHARMACEUTICAL ARTIFICIAL INTELLIGENCE

SOURCE: QuantHealth

Copyright Business Wire 2026.

PUB: 03/24/2026 09:00 AM/DISC: 03/24/2026 09:02 AM

http://www.businesswire.com/news/home/20260324314748/en